Phase II Trial of Epigallocatechin-3-Gallate in Acute Radiation-Induced Esophagitis for Esophagus Cancer

다국어 초록 (Multilingual Abstract)

Acute radiation-induced esophagitis (ARIE) is among the most serious form of toxicities associated with definitive radiotherapy or chemoradiotherapy used for treatment of patients with esophageal cancer. Our preliminary phase I and II trials of lung cancer patients who received radiotherapy indicated epigallocatechin-3-gallate (EGCG) as a promising therapeutic option against ARIE. Therefore, we conducted a prospective phase II study to validate the efficacy and safety of EGCG in the treatment of ARIE. The patients who received chemoradiotherapy or definitive radiotherapy for treatment of esophageal cancer in the Shandong Cancer Hospital and Institute in China were enrolled for the present study. EGCG (440 μM) was administered with first onset of ARIE and then at weeks after final radiotherapy. The patients were monitored every week for dysphagia, Radiation Therapy Oncology Group (RTOG) score, and esophagitis-related pain. Moreover, tumor response and the effect on survival following the treatment were also evaluated. Comparison of the RTOG score in the first, second, third, fourth, fifth, and even sixth week after EGCG prescription and the first and second week after radiotherapy with baseline indicates a significant reduction. The tumor response rate was 86.3%. The overall survival rate in 1, 2, and 3 years was found to be 74.5%, 58%, and 40.5%. Oral administration of EGCG solution seems to be feasible for treating ARIE in patients with esophageal cancer who receive radiation therapy. EGCG might be an ARIE-reliever without compromising the efficacy of radiation therapy. A randomized study with a control group is needed for further evaluation.

참고문헌 (Reference)

1 Lucock MD, "The antifolate activity of tea catechins" 65 : 8573-, 2005

2 Naasani I, "Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins" 249 : 391-396, 1998

3 Rose J, "Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy" 91 : 282-287, 2009

4 Shammas MA, "Specific killing of multiple myeloma cells by(-)-epigallocatechin-3-gallate extracted from green tea : Biologic activity and therapeutic implications" 108 : 2804-2810, 2006

5 Movsas B, "Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation : Radiation therapy oncology group trial 98-01" 23 : 2145-2154, 2005

6 Leong S, "Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer" 21 : 1767-1774, 2003

7 van Hagen P, "Preoperative chemoradiotherapy for esophageal or junctional cancer" 366 : 2074-2084, 2012

8 Shanafelt TD, "Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia" 27 : 3808-3814, 2009

9 Zhao H, "Phase I study of topical epigallocatechin-3-gallate(EGCG)in patients with breast cancer receiving adjuvant radiotherapy" 89 : 20150665-, 2016

10 Shanafelt TD, "Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0to II chronic lymphocytic leukemia" 119 : 363-370, 2013

11 Yang CS, "Inhibition of carcinogenesis by tea" 389 : 134-135, 1997

12 Yang CS, "Inhibition of carcinogenesis by tea" 42 : 25-54, 2002

13 Zhou SB, "Influential factors on radiotherapy efficacy and prognosis in patients with secondary lymph node metastasis after esophagectomy of thoracic esophageal squamous cell carcinoma" 10 : 217-225, 2018

14 Ahmad N, "Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells" 89 : 1881-1886, 1997

15 Lamy S, "Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation" 62 : 381-385, 2002

16 Challand T, "Esophageal toxicity of radiation therapy : clinical risk factors and management" 16 : 364-371, 2012

17 Wanqi Z, "Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy" 7 : 48607-48613, 2016

18 Jung YD, "EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells" 84 : 844-850, 2001

19 김현주, "Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy" 대한암학회 49 (49): 669-677, 2017

20 Li QQ, "Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma" 23 : 253-259, 2010

21 Chen Y, "Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: A randomized, multicenter, phase III clinical trial" 28 : JCO1802122-, 2019

22 Cooper JS, "Chemoradiotherapy of locally advanced esophageal cancer : Long-term follow-up of a prospective randomized trial(RTOG 85-01). Radiation Therapy Oncology Group" 281 : 1623-1627, 1999

23 Meng X, "Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma : A prospective, multicenter phase II trail" 109 : 275-280, 2013

24 Siegel RL, "Cancer statistics" 67 : 7-30, 2017

25 Leone M, "Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins" 63 : 8118-8121, 2003

26 Jen-KunLin, "Cancer Chemoprevention by Tea Polyphenols Through Modulating Signal Transduction Pathways" 대한약학회 25 (25): 561-571, 2002

27 Naasani I, "Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo" 63 : 824-830, 2003

28 Guerra JL, "Association between single nucleotide polymorphisms of the transforming growth factor beta1 gene and the risk of severe radiation esophagitis in patients with lung cancer" 105 : 299-304, 2012

29 Zhang G, "Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy" 12 : 163-176, 2012

30 Sasse A, "Amifostine reduces side effects and improves complete response rate during radiotherapy : Results of a metaanalysis" 64 : 784-791, 2006

31 Hensley ML, "American Society of Clinical Oncology 2008 clinical practice guideline update : Use of chemotherapy and radiation therapy protectants" 27 : 127-145, 2009

32 Zhao H, "A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer" 114 : 351-356, 2015

33 Zhao H, "A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer" 110 : 132-136, 2014